Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

BACKGROUND: The use of imatinib, an ABL tyrosine kinase inhibitor, has led to a dramatic change in the management of BCR-ABL-positive leukemia patients. However, resistance to imatinib mediated by mutations in the BCR-ABL domain has become a major problem in the treatment of these patients. METHODS:...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Kimura, Shinya, Maekawa, Taira, Ohyashiki, Kazuma
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2013
Konular:
Primary Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3635933/
https://ncbi.nlm.nih.gov/pubmed/23556431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2867-13-32
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller